Premium
Triptans in children and adolescents
Author(s) -
Gladstein Jack
Publication year - 2007
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.20199
Subject(s) - triptans , migraine , medicine , placebo , sedation , drug class , acute migraine , anesthesia , drug , intensive care medicine , pediatrics , psychiatry , alternative medicine , pathology
The advent of triptans in the 1990 s changed the approach to treating the migraine sufferer. Before triptan drugs, an acute attack of migraine was treated with drugs to put the patient to sleep until the migraine passed. This rendered the patient unable to resume activities such as school or work. Migraineurs had significant morbidity from treated as well as untreated attacks. With the use of this class of medications, headache could be treated quickly without the accompanied sedation from the medications. This has allowed people to get back to their busy lives, and migraine disability from medications has been lowered. Unfortunately, pediatric triptan trials have for the most part failed to demonstrate efficacy when compared to placebo. Nevertheless, these drugs are used for children and adolescents without FDA approval. Study design and consent adapted form adult studies may have made the placebo response rate higher than it needed to be. Drug Dev Res 68:346–349, 2007. © 2007 Wiley‐Liss, Inc.